Safety and Efficacy of Eus-Guided Ablation of Pancreatic Lesions With Ethanol versus Ethanol With Paclitaxel: A Systematic Review and Meta-Analysis
Author Type(s)
Resident/Fellow
Document Type
Article
Publication Date
1-1-2022
Journal Title
Endoscopic Ultrasound
Department
Medicine
Abstract
BACKGROUND AND OBJECTIVES: EUS-guided ethanol ablation has emerged as an alternative method for pancreatic lesions. Recently, paclitaxel was added to ethanol to assess ablative effects in pancreatic lesions. We performed a systematic review and meta-analysis on EUS-guided ethanol ablation (EUS E) versus EUS-guided ethanol with paclitaxel (EUS EP) ablation for the management of pancreatic lesions.
METHODS: Comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Google Scholar, and Web of Science databases (from inception to May 2020). The primary outcome evaluated complete ablation of the lesions radiologically and the secondary outcome evaluated adverse events (AEs).
RESULTS: Fifteen studies on 524 patients were included in our analysis. The pooled complete ablation rate was 58.89% (95% confidence interval (CI) = 38.72-77.80, I
CONCLUSION: Complete ablation rates were comparable among both groups. AE rates were higher in the EUS EP group. Further randomized controlled trials are needed to validate our findings.
Recommended Citation
Saghir, S., Dhindsa, B., Daid, S., Naga, Y., Dhaliwal, A., Mashiana, H., Bhogal, N., Sayles, H., Ramai, D., Singh, S., Bhat, I., Rangray, R., McDonough, S., & Adler, D. (2022). Safety and Efficacy of Eus-Guided Ablation of Pancreatic Lesions With Ethanol versus Ethanol With Paclitaxel: A Systematic Review and Meta-Analysis. Endoscopic Ultrasound, 11 (5), 371-376. https://doi.org/10.4103/EUS-D-20-00185
